背景:大多数抗高血压药可以诱导皮肤光敏性,这可能会增加黑色素瘤的风险。然而,确证有限。我们研究了使用抗高血压药与黑色素瘤风险之间的关联。
方法:使用挪威癌症登记处的数据进行了一项全国性的巢式病例对照研究。2004-15年度国家登记处和挪威处方数据库。每个黑色素瘤病例随机选择10个对照,性别和出生年份相匹配。该研究包括12048例病例和117895例对照。我们用95%置信区间(CI)估计了比率(RR)。针对环境紫外线辐射(UVR)调整所有分析。我们还进行了主动比较分析,和敏感性分析,只包括新用户,区分独家用户和混合用户,允许不同的延迟周期,并按黑色素瘤亚型和临床分期进行亚组分析。
结果:与未使用相比,我们观察到利尿剂使用者的黑色素瘤风险略有增加(RR1.08,CI1.01-1.15),钙通道阻滞剂(RR1.10,CI1.04-1.18)和影响肾素-血管紧张素系统的药物(RR1.10,CI1.04-1.16),但不是β受体阻滞剂(RR0.97,CI0.92-1.03)。我们发现黑素瘤亚型或临床分期之间的关联没有异质性,并且累积确定日剂量(DDDs)与黑素瘤之间没有剂量反应关系。在累积DDDs和环境UVR之间没有发现相互作用。
结论:弱关联,缺乏剂量反应关系,缺乏与环境UVR的相互作用,在这项全国性研究的DDD分析中,不支持抗高血压药与黑色素瘤风险之间存在因果关系.
Most antihypertensives can induce dermal
photosensitivity, which may increase melanoma risk. However, corroborating evidence is limited. We examined the associations between use of antihypertensives and melanoma risk.
A nationwide nested
case-control study was conducted using data from the Cancer Registry of Norway, the National Registry and the Norwegian Prescription Database in 2004-15. Ten controls were randomly selected for each melanoma
case, matched on sex and birth year. The study included 12 048 cases and 117 895 controls. We estimated rate ratios (RRs) with 95% confidence intervals (CIs). All analyses were adjusted for ambient ultraviolet radiation (UVR). We additionally performed active comparator analyses, and sensitivity analyses by only including new users, distinguishing between exclusive and mixed users, allowing for different latency periods, and subgroup analyses by melanoma subtype and clinical stage.
Compared with non-use, we observed a slightly increased melanoma risk in users of diuretics (RR 1.08, CI 1.01-1.15), calcium-channel blockers (RR 1.10, CI 1.04-1.18) and drugs affecting the renin-angiotensin system (RR 1.10, CI 1.04-1.16), but not for beta blockers (RR 0.97, CI 0.92-1.03). We found no heterogeneity of associations by melanoma subtype or clinical stage and no dose-response relationship between the cumulative defined daily doses (DDDs) and melanoma. No interaction was found between cumulative DDDs and ambient UVR.
Weak associations, with lack of a dose-response relationship and lack of interactions with ambient UVR, in the DDD analysis in this nationwide study do not support a causal relationship between antihypertensives and melanoma risk.